Swiss pharmaceutical giant Novartis on Friday reported fourth-quarter results after repeatedly raising its full-year guidance.

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

A separate ruling on Wednesday from U.S. District Judge Dabney Friedrich in Washington had cleared a hurdle for MSN to introduce the first U.S. generic of Switzerland-based Novartis' best-selling ...

The acting chair of the, Mark Uyeda, took the first step Tuesday to rolling back a rule that would require thousands of ...

Matthias Leuenberger, Delegate Novartis Switzerland, will assume the role of Country President for Switzerland, left vacant following Wyss’s departure. Klinger’s role will be expanded to allow ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth. After signing 30 deals ...

with the lead indication for prevention of stroke and systemic embolism in patients with atrial fibrillationAcquisition adds a late-stage asset and is aligned with Novartis strategic focus ...